viewInstem PLC

Instem plc - Update to Results Announcement Date

RNS Number : 4577H
Instem plc
25 March 2020

Instem plc


("Instem" or the "Company")


Update to Results Announcement Date


Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, provides the following update to the market.


As announced by the UK Financial Conduct Authority ("FCA") on 23 March, the FCA has written to all listed companies it was aware of that were planning to announce preliminary results in the next few days. They strongly requested that all such companies should observe a moratorium on the publication of their preliminary statements for at least two weeks.  This order is to ease the practical challenges faced by those companies and the audit profession during the current COVID-19 crisis.


Whilst the FCA letter was targeted at main market listed entities, Instem has decided to follow that guidance and will not now announce preliminary results on 30th March 2020.


In line with the guidance provided in the Company's Trading update issued on 13th January 2020, subject to audit, Instem expects to report 2019 Revenues of approximately £25.7m and Adjusted EBITDA* of approximately £4.9m, with a 2019 year-end closing cash position of £6.0m.


The Board will update the market with a date for the release of its audited 2019 financial statements as soon as practicable.


*Adjusted EBITDA is Earnings before Interest, Tax, Depreciation, Amortisation and Non-recurring costs


For further information, please contact:


Instem plc

Via Walbrook

Phil Reason, CEO


Nigel Goldsmith, CFO






N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Peter Steel

Rachel Hayes






Walbrook Financial PR

+44 (0) 20 7933 8780

Tom Cooper

[email protected]

Nick Rome

Nicholas Johnson



About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.


Instem solutions are in use by over 500 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.


Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.


To learn more about Instem solutions and its mission, please visit www.instem.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Instem PLC

Price: 472.51

Market: AIM
Market Cap: £78.79 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Investor Update: CentralNic Group looks to acquire website provider Team...

Headlines from the Proactive UK newsroom. CentralNic Group (LON:CNIC) has confirmed advanced discussions are underway to acquire website provider Team Internet. The AIM-listed domain name specialist said further announcements will be made in due course. Life sciences group Instem (LON:INS)...

on 15/11/19